Graph AI, a California-based AI life sciences company focused on patient safety and pharmacovigilance, has secured $3 million in seed funding led by Bessemer Venture Partners. The investment will enable the company to accelerate product innovation, expand its engineering team, and drive global market adoption of its AI-native drug safety monitoring platform.
Founded in 2024 by industry veterans Raghav Parvataraju (CEO), Vijay Ponukumati (CTO), Mohan Konyala (CPO), and Ashutosh Bordekar (CFO), Graph AI addresses critical inefficiencies in the $8 billion pharmacovigilance market. The founding team brings significant experience from leading global organizations including LTI Mindtree, Infosys, ServiceNow, Google, and Cisco.
Addressing Market Fragmentation in Drug Safety
Pharmacovigilance, mandated by global drug regulatory authorities, requires pharmaceutical companies to continuously monitor, detect, and report adverse drug events (ADE) across a drug's entire lifecycle, from clinical trials to post-market use. However, this market remains highly fragmented and labor-intensive, with companies typically relying on service firms to manually extract and process data from unstructured sources including call center transcripts, legal filings, medical literature, emails, and social media posts.
These traditional workflows employ vast teams of pharmacology graduates who sift through hundreds of thousands of documents to assess the causality of ADEs, prepare and submit regulatory reports across multiple jurisdictions, and recommend follow-up actions. The existing processes are highly fragmented, labor-intensive, and reactive, resulting in operational silos that slow down case processing, signal detection, regulatory reporting, and overall compliance.
Graph Safety Platform Delivers Measurable Results
Graph AI's flagship platform, Graph Safety, is redefining pharmacovigilance through context-aware artificial intelligence and intelligent automation, delivering a truly end-to-end safety solution. The platform automates key processes including ADE case processing, signal detection, aggregate reporting, and regulatory compliance, while building a centralized safety intelligence database over time.
By keeping a human-in-the-loop only for select regulatory-mandated steps, Graph enables pharmaceutical companies to transition from manual, error-prone, and time-intensive workflows to highly automated, AI-driven systems that enhance the efficiency and accuracy of medical reviews while ensuring full regulatory compliance.
In just over a year since its inception, Graph AI has delivered remarkable traction and tangible results. Enterprise customers have reported up to 70% efficiency gains, 90% faster regulatory reporting, and substantial cost savings, all while maintaining end-to-end traceability and audit readiness. The platform has built a strong pipeline across more than 7,000 marketed drugs, reflecting growing demand from enterprise customers and the expanding scope of pharmacovigilance modernization.
Industry Transformation Through AI-Native Solutions
"The life sciences industry continues to grapple with outdated technology, fragmented point solutions, data silos, and manual handoffs that hinder decision-making and elevate compliance risks," the founders said in a joint statement. "At Graph AI, we're addressing these challenges with a unified, AI-native safety platform that integrates context, compliance, and intelligence into a single seamless ecosystem. Our vision is to make patient safety smarter, faster, and more connected, empowering pharmaceutical and biotech enterprises to achieve safer outcomes, stronger regulatory confidence, and exponential efficiency across safety operations."
Nithin Kaimal, Partner and COO at Bessemer Venture Partners India, expressed enthusiasm about the partnership: "We're excited to partner with Graph AI as they redefine labour intensive and inefficient pharmacovigilance workflows through AI-native solutions that prioritize both accuracy and scalability. At Bessemer, we're deeply optimistic about the transformative potential of AI products to reimagine traditional services models as for the first time, delivery is shifting from labour arbitrage to intelligence arbitrage, empowering enterprises to work with firms that deliver faster, smarter, and more adaptive solutions."
The funding round comes as AI-powered solutions are reshaping the drug safety and compliance landscape, with Graph AI positioning itself as a prime example of the new wave of AI-native challengers transforming the pharmaceutical and life sciences industry.
